InGeneron said today that it landed a collaboration with the German Accelerator Life Sciences program, establishing an additional U.S. presence in Cambridge, Mass. The initiative is supported by the German Federal Ministry for Economic Affairs & Energy.
The GALS program will provide InGeneron with a group of mentors to help leverage its network within the industry and support the company’s U.S. presence and development in Europe. GALS will continue to support InGeneron as the company launches clinical development in the U.S. and expands its distribution network, the program said.
Houston, Texas-based InGeneron develops regenerative cell therapies for orthopedic and wound healing indications.
“Our new presence in Cambridge will help us access one of the world’s leading life sciences and biotechnology hubs and tap into the local talent pool,” InGeneron CEO Michael Coleman said in prepared remarks. “Additionally, being accepted into the GALS program is a commendation for our teams on both sides of the Atlantic. The broad network and expertise of GALS represents a significant opportunity for the company.”
“We are excited to start our collaboration with InGeneron. The company’s adipose-derived regenerative cell-based technology has great potential across several indications. We are confident that GALS can add significant value and help InGeneron establish its innovative approach in the US and Europe,” GALS CEO Christoph Lengauer added.
